Section Arrow
EDSA.NASDAQ
- Edesa Biotech
Quotes are at least 15-min delayed:2026/04/21 19:27 EDT
After Hours
Last
 7.5
-0.15 (-1.96%)
Bid
7.11
Ask
7.54
High 7.72 
Low 7.0366 
Volume 6.94K 
Regular Hours (Closed)
Last
 7.65
+0.9 (+13.33%)
Day High 
7.7 
Prev. Close
6.75 
1-M High
8.1 
Volume 
297.74K 
Bid
7.11
Ask
7.54
Day Low
6.7424 
Open
6.8 
1-M Low
5.0201 
Market Cap 
59.98M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 5.78 
20-SMA 5.94 
50-SMA 4.5 
52-W High 9.37 
52-W Low 0.72 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.07/-0.69
Enterprise Value
59.98M
Balance Sheet
Book Value Per Share
0.52
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
After Hours 0.2114 +0.0146 +7.42%
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
After Hours 2.66 -0.03 -1.12%
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
After Hours 0.3374 -0.0013 -0.38%
GERNGeron Corp1.5-0.06-3.85%-- 
After Hours 1.5092 +0.0092 +0.61%
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
After Hours 5.6992 -0.2908 -4.85%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.